List of Excipients in Branded Drug NORVASC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PFIZER LABORATORIES DIV PFIZER INC	NORVASC	amlodipine besylate	0069-1520	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
PFIZER LABORATORIES DIV PFIZER INC	NORVASC	amlodipine besylate	0069-1520	CELLULOSE, MICROCRYSTALLINE
PFIZER LABORATORIES DIV PFIZER INC	NORVASC	amlodipine besylate	0069-1520	MAGNESIUM STEARATE
PFIZER LABORATORIES DIV PFIZER INC	NORVASC	amlodipine besylate	0069-1520	SODIUM STARCH GLYCOLATE TYPE A POTATO
Rebel Distributors Corp	NORVASC	amlodipine besylate	21695-151	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Rebel Distributors Corp	NORVASC	amlodipine besylate	21695-151	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	NORVASC	amlodipine besylate	21695-151	MAGNESIUM STEARATE

Norvasc Excipient Strategy and Commercial Opportunities: Amlodipine Patent, Formulation, and Generic Market Analysis

Last updated: September 5, 2026

Norvasc is Pfizer’s branded amlodipine besylate product for hypertension and coronary artery disease. Its commercial protection has ended: FDA approval dates to 1992, the core amlodipine patent expired years ago, and multiple generic products compete in the U.S. [1][2] The strongest opportunities are not in standard amlodipine tablets. They are in differentiated dosage forms, pediatric delivery, fixed-dose combinations, excipient substitution, contract manufacturing, and supply-chain performance.

What is Norvasc, and which excipients does the product use?

Norvasc contains amlodipine besylate, equivalent to 2.5 mg, 5 mg, or 10 mg of amlodipine. It is an oral tablet indicated for hypertension and chronic stable or vasospastic angina. The U.S. labeling identifies microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate as inactive ingredients. [1]

Product attribute	Norvasc profile
Active ingredient	Amlodipine besylate
Therapeutic class	Dihydropyridine calcium-channel blocker
U.S. dosage form	Immediate-release tablet
Strengths	2.5 mg, 5 mg, 10 mg
Administration	Once daily
Original U.S. approval	1992
Reference sponsor	Pfizer
Core excipients	Microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, magnesium stearate
Generic pathway	ANDA
Current protection	Mature generic market

The formulation uses a conventional, low-cost tablet platform. Microcrystalline cellulose provides compactability and tablet structure. Dibasic calcium phosphate functions as a low-hygroscopic filler. Sodium starch glycolate promotes disintegration. Magnesium stearate reduces friction during compression and ejection.

This composition is well suited to high-volume manufacturing. It also creates formulation whitespace for products that improve swallowability, dose flexibility, taste, stability, or administration in patients who cannot use conventional tablets.

What patents protect Norvasc and amlodipine?

The original amlodipine patent estate no longer blocks generic entry in the United States. Amlodipine was covered by Pfizer-related patent rights, including U.S. Patent No. 4,572,909, but those rights expired before the current generic market matured. [2][3]

IP category	Commercial status
Amlodipine compound patent	Expired
Original Norvasc formulation protection	Expired or commercially nonblocking
FDA marketing exclusivity	Expired
Standard generic entry barrier	None of practical significance
Method-of-use patents	No material active barrier for standard hypertension use
New formulation patents	Potentially available for differentiated products
Manufacturing patents	Potentially relevant to process advantages

The relevant business question is whether an unexpired, enforceable patent covers the specific reference product and can delay an ANDA. For standard Norvasc tablets, the practical answer is no. The Orange Book records patents and exclusivity associated with approved products, but expired rights do not prevent generic approval. [2]

When did Norvasc lose exclusivity?

Norvasc lost meaningful U.S. market exclusivity after expiration of its core patent protection and the subsequent approval of generic amlodipine products. FDA approved the reference product in 1992, and generic products entered after the relevant patent period. [1][2]

Norvasc exclusivity timeline

Milestone	Timing	Commercial effect
FDA approval of Norvasc	1992	Pfizer obtained initial U.S. market access
Core patent period	Expired	Compound-level exclusivity ended
Generic ANDA approvals	Subsequent years	Price competition began
Current status	Mature market	Differentiation depends on product utility, supply, and contracting

Any pediatric exclusivity associated with a specific regulatory event would not restore broad exclusivity for the standard tablet after expiration of the underlying patent and regulatory periods. Generic applicants can rely on FDA findings for the reference-listed drug, subject to applicable labeling and patent certifications. [2][4]

What is the Orange Book status of Norvasc?

Norvasc remains an FDA reference-listed drug, but its standard tablet presentations do not have a commercially meaningful unexpired patent barrier comparable to a recently launched branded product. [2]

An ANDA applicant seeking approval for amlodipine tablets typically must address any relevant listed patents through the applicable certification. For the mature Norvasc tablet market, ordinary ANDA approval is more important than a live Paragraph IV litigation strategy.

Are there Paragraph IV challenges to Norvasc?

Paragraph IV certifications are relevant when a generic applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For legacy Norvasc tablets, the commercial importance of new Paragraph IV litigation is low because the principal patent barriers have expired.

The relevant competitive mechanism is ordinary generic approval, not an ongoing patent contest. A new amlodipine formulation could present a different litigation profile if it relies on patents covering a dosage form, formulation, delivery system, or method of use.

What excipient strategies can differentiate amlodipine products?

The strongest excipient strategy depends on the target patient, regulatory pathway, and manufacturing objective. A new excipient system should improve a measurable product attribute, such as disintegration, content uniformity, stability, swallowability, taste, or dose flexibility.

Pediatric oral liquid

Amlodipine is used in pediatric hypertension, but conventional tablets create swallowing and dose-measurement problems. A ready-to-use oral suspension or solution could target:

• Children unable to swallow tablets
• Weight-based dosing
• Caregivers who require liquid administration
• Hospitals and specialty pharmacies
• Patients receiving enteral feeding

Relevant excipient functions include suspension control, wetting, buffering, preservation, sweetening, and flavoring. Key development risks are chemical stability, microbial control, sedimentation, redispersibility, dose uniformity, and palatability.

A liquid product may qualify for a 505(b)(2) NDA if it relies partly on FDA findings for an approved amlodipine product while introducing a new dosage form or formulation. The sponsor would still need to establish formulation-specific quality, safety, stability, and bioavailability requirements. [4]

Orally disintegrating tablet

An orally disintegrating tablet could improve administration for older adults, patients with dysphagia, and patients who lack access to water. A potential excipient platform includes:

• Low-moisture fillers
• Crospovidone or croscarmellose sodium
• Direct-compression binders
• Mannitol or similar mouthfeel agents
• Taste-masking materials
• Lubricants optimized for rapid disintegration

Low-dose content uniformity is a central issue. The 2.5 mg strength presents greater blend-uniformity and segregation risk than the 10 mg strength. The tablet must retain adequate mechanical strength while dispersing rapidly in the mouth.

Taste-masked granules or sprinkle formulation

Taste masking could use polymer coating, ion-exchange technology, lipid barriers, or multiparticulate granules. The product must limit release in the mouth while allowing prompt gastrointestinal release.

A sprinkle product could be supplied in unit-dose sachets or capsules opened and mixed with soft food. Commercial value would depend on dose uniformity, food compatibility, stability after opening, and recovery of the full dose.

Excipient substitution and supply-chain resilience

Generic manufacturers can qualify alternative grades of:

• Microcrystalline cellulose
• Dibasic calcium phosphate
• Sodium starch glycolate
• Magnesium stearate

Supplier qualification must consider particle-size distribution, density, moisture, flow, microbiological quality, compaction, and lubricant sensitivity. A dual-source strategy can reduce dependence on one excipient supplier, but changing excipient grade may alter tablet hardness, friability, disintegration, dissolution, and process performance.

What formulations are protected by new amlodipine patents?

A new amlodipine patent is more defensible when it claims a defined technical solution rather than a routine substitution of one filler for another.

Formulation target	Potential patent subject matter
Pediatric liquid	Stability range, pH, preservative system, redispersibility
ODT	Taste masking, low-dose uniformity, defined disintegration performance
Fixed-dose combination	Active-ingredient compatibility and stability
Modified release	Release-controlling matrix or multiparticulate structure
Manufacturing process	Granulation, drying, coating, or compression parameters linked to performance
Low-dose tablet	Blend-control method and content-uniformity process
Sprinkle formulation	Food compatibility, release profile, and dose recovery

A patent must satisfy novelty, nonobviousness, enablement, and written-description requirements. Claims that merely recite common excipients at routine concentrations may have limited durability. Claims tied to unexpected stability, bioavailability, taste performance, or manufacturing yield are more valuable.

How does Norvasc compare with competing calcium-channel blockers?

Amlodipine competes with generic felodipine, nifedipine, and other antihypertensive products, as well as fixed-dose combinations involving angiotensin receptor blockers, ACE inhibitors, beta blockers, and diuretics.

Product	Active ingredient	Commercial formulation opportunity	IP position
Norvasc	Amlodipine besylate	ODT, liquid, combination tablet	Mature generic market
Procardia XL and generics	Nifedipine	Modified release, dose flexibility	Mature generic market
Plendil and generics	Felodipine	Extended-release delivery	Mature generic market
Amlodipine combinations	Amlodipine plus another active	Fixed-dose combinations	Product-specific IP may apply

Amlodipine’s long half-life and once-daily dosing reduce the commercial need for extended release. Patient-centric delivery, combination therapy, and manufacturing economics are more attractive targets than a conventional sustained-release tablet.

What FDA regulatory pathways apply to new Norvasc formulations?

A standard generic tablet normally uses an ANDA and must demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug. [4]

A differentiated formulation may use one of three routes:

1. ANDA. Appropriate when the product matches the reference drug in dosage form, strength, route, and relevant characteristics.
2. 505(b)(2) NDA. Appropriate when the sponsor relies partly on FDA findings for an approved product but introduces a meaningful change, such as a liquid, ODT, or new delivery system.
3. Full NDA. Generally reserved for products that cannot rely sufficiently on prior FDA findings.

FDA review will address chemistry, manufacturing and controls, excipient safety, stability, comparative performance, labeling, and bioequivalence or clinical bridging as applicable. Novel excipients can increase development risk because additional toxicology or exposure justification may be required.

What generic entry risks exist for Norvasc?

Generic entry risk has already been realized. The commercial risks for a new branded or differentiated amlodipine product are:

• Aggressive generic pricing
• Pharmacy substitution
• Low reimbursement for standard tablets
• Limited willingness to pay for minor excipient changes
• Manufacturing disruption
• Weak protection for routine composition claims
• FDA review risk for novel excipient systems
• Low switching incentive among patients who tolerate generic tablets

A formulation must solve a defined problem. A pediatric liquid for patients unable to swallow tablets has a stronger value proposition than a tablet using a different filler without a demonstrated patient or manufacturing benefit.

Which companies are challenging Norvasc commercially?

Competition comes primarily from generic manufacturers and distributors rather than a single branded challenger. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations identifies approved generic equivalents and therapeutic-equivalence information. [2]

The competitive field includes large generic manufacturers, specialty generic suppliers, contract development and manufacturing organizations, and regional pharmaceutical companies. Competitive advantage is likely to come from:

• Reliable supply of all three strengths
• Low tablet cost
• Consistent dissolution
• Simplified excipient sourcing
• Hospital and retail contracting
• Liquid or ODT differentiation
• Access to combination-product portfolios

A company entering only the standard 5 mg and 10 mg tablets would compete mainly on price and supply reliability. A company entering with a pediatric liquid, ODT, or combination product could compete on access and product utility.

What licensing deals and commercial partnerships are relevant?

Norvasc is a legacy Pfizer brand, while standard amlodipine tablets are widely available through generic manufacturers. Relevant partnership opportunities are likely to involve:

• Licensing pediatric liquid technology
• Contract development of ODT or taste-masked products
• Regional commercialization rights
• Co-development of fixed-dose combinations
• Dual-source excipient supply
• Hospital distribution for specialized dosage forms

A license is not required to manufacture a standard generic amlodipine tablet after applicable patent and regulatory requirements are satisfied. Licensing becomes more relevant when a company seeks proprietary delivery technology, a combination product, or jurisdiction-specific formulation rights.

How strong is the Norvasc patent estate?

The legacy patent estate is weak as a barrier to standard generic tablets because the core rights have expired. Its value is historical rather than prospective.

Patent-estate factor	Assessment
Compound protection	Expired
Standard tablet protection	Expired or nonblocking
Method-of-use protection	Limited practical relevance
Formulation whitespace	Significant
Manufacturing-process opportunity	Moderate
Litigation risk for standard generics	Low
Litigation risk for new differentiated products	Product-specific
Value of formulation patents	Potentially meaningful if narrow and validated

New IP should be built around a differentiated product with measurable performance. A broad claim covering amlodipine with conventional excipients is unlikely to create a strong commercial moat.

What is the revenue exposure for Pfizer and generic manufacturers?

Pfizer does not generally report Norvasc as a separately disclosed current revenue segment in its public financial reporting. Product-specific revenue exposure therefore cannot be reliably quantified from Pfizer’s segment disclosures. [5]

For generic manufacturers, revenue exposure is more relevant at the portfolio level. Standard amlodipine tablets are high-volume, low-margin products. Revenue depends on:

• Unit volume
• Wholesale acquisition price
• Reimbursement and payer mix
• Number of approved suppliers
• Market-share distribution
• Institutional contracting
• Inventory and shortage conditions

The 5 mg strength is typically important for volume. The 2.5 mg strength may support pediatric and low-dose use, while the 10 mg strength serves patients requiring higher dosing. A differentiated product can command better pricing only if it addresses a clinical or operational need that generic tablets do not solve.

What manufacturing and IP barriers affect amlodipine opportunities?

Manufacturers must manage low-dose blending, segregation, compression variability, lubrication, dissolution, stability, and packaging.

For liquid products, the principal barriers are chemical stability and microbial control. For ODTs, they are tablet strength, moisture sensitivity, taste, and content uniformity. For fixed-dose combinations, compatibility between active ingredients and excipient systems is central.

The strongest commercial package combines:

1. A product-specific formulation patent.
2. A validated manufacturing process.
3. Reliable active-ingredient and excipient sourcing.
4. A regulatory route matched to the product change.
5. A distribution channel that values the differentiated dosage form.

Key Takeaways

• Norvasc is an established amlodipine besylate tablet with expired core exclusivity and extensive generic competition.
• Its labeled excipient platform is simple: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.
• The standard tablet market is primarily a price, supply, and contracting business.
• The strongest formulation opportunities are pediatric liquids, ODTs, taste-masked products, sprinkle formulations, and fixed-dose combinations.
• New patents should target measurable technical effects such as improved stability, dissolution, taste, dose uniformity, or manufacturing performance.
• Standard generic entry does not depend on a live Paragraph IV contest against Norvasc.
• No biosimilar pathway applies because amlodipine is a chemically synthesized small molecule.
• Excipient substitution can reduce cost and supply risk but requires comparative performance and change-control work.
• Pfizer’s current Norvasc revenue is not separately disclosed.

FAQs

Does Norvasc contain lactose?

The cited U.S. Norvasc labeling lists microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate. Lactose is not listed among those inactive ingredients. [1]

Can a company launch an amlodipine oral suspension without Pfizer’s permission?

A company can pursue an independently developed amlodipine oral suspension subject to FDA approval, intellectual-property review, manufacturing requirements, and any applicable formulation or delivery patents. Expired Norvasc compound protection does not by itself block the product.

Is amlodipine suitable for a 505(b)(2) application?

Amlodipine may be suitable for a 505(b)(2) application when the proposed product changes the dosage form, formulation, or delivery system and relies partly on FDA findings for an approved amlodipine product. The route depends on the product’s specific differences and evidence package. [4]

Can excipient changes alone create market exclusivity for amlodipine?

Routine excipient changes rarely create durable exclusivity. A stronger opportunity requires a novel, nonobvious formulation or manufacturing feature linked to a demonstrated technical benefit and enforceable patent claims.

Does amlodipine face biosimilar competition?

No. Amlodipine is a chemically synthesized small molecule. Competing products are regulated as generic drugs, primarily through ANDAs, rather than as biosimilars under the Public Health Service Act.

References

1. Pfizer Inc. (2024). Norvasc (amlodipine besylate) tablets: U.S. prescribing information. U.S. Food and Drug Administration/DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (1986). U.S. Patent No. 4,572,909: Amlodipine. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application and 505(b)(2) application regulatory guidance. FDA.

5. Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Pfizer.